Table 1.
Baseline Characteristics, According to Tertiles of Serum suPAR Concentration
| Characteristic | Entire Cohort (n=751) | Baseline Serum suPAR Concentration, pg/mL | P Value | ||
|---|---|---|---|---|---|
| <1162 (n=250) | 1163–1863 (n=251) | ≥1874 (n=250) | |||
| Demographic data | |||||
| Age, y | 61.4±11.4 | 60.7±10.9 | 61.5±11.9 | 62.1±11.2 | 0.40 |
| Men | 395 (52.6) | 142 (56.8) | 131 (52.2) | 122 (48.8) | 0.07 |
| BMI, kg/m2 | 25.2±3.7 | 25.5±3.3 | 25.2±3.9 | 25.0±3.9 | 0.23 |
| Smoking status | 428 (57.0) | 145 (58.0) | 133 (53.0) | 150 (60.0) | 0.39 |
| Alcohol status | 272 (36.2) | 88 (35.2) | 83 (33.1) | 101 (40.4) | 0.17 |
| SBP, mm Hg | 130.1±18.2 | 125.5±14.6 | 129.0±17.4 | 135.9±20.5 | <0.001 |
| DBP, mm Hg | 75.6±11.7 | 74.9±9.3 | 76.3±10.8 | 75.5±11.7 | 0.33 |
| CKD stages | <0.001 | ||||
| I | 97 (12.9) | 74 (29.6) | 21 (8.4) | 02 (0.8) | |
| II | 180 (24.0) | 98 (39.2) | 57 (22.7) | 25 (10.0) | |
| IIIa | 161 (21.4) | 62 (24.8) | 68 (27.1) | 31 (12.4) | |
| IIIb | 116 (15.4) | 12 (4.8) | 59 (23.5) | 45 (18.0) | |
| IV | 130 (17.3) | 2 (0.8) | 40 (15.9) | 88 (35.2) | |
| V | 67 (8.9) | 2 (0.8) | 6 (2.4) | 59 (23.6) | |
| Comorbidities | |||||
| Hypertension | 669 (89.1) | 219 (87.6) | 222 (88.4) | 228 (91.2) | 0.20 |
| Diabetes mellitus | 363 (48.3) | 108 (43.2) | 105 (41.8) | 150 (60.0) | <0.001 |
| Dyslipidemia | 434 (57.8) | 157 (62.8) | 140 (55.8) | 137 (54.8) | 0.70 |
| CHF | 9 (1.2) | 3 (1.2) | 1 (0.4) | 5 (2.0) | 0.41 |
| CAD | 43 (5.7) | 21 (8.4) | 9 (3.6) | 13 (5.2) | 0.06 |
| CVA | 36 (4.8) | 13 (5.2) | 12 (4.8) | 11 (4.4) | 0.68 |
| Laboratory data | |||||
| eGFR, mL/min per 1.73 m2 | 52.8±28.5 | 75.1±23.6 | 52.2±22.7 | 31.1±19.9 | <0.001 |
| UACR, mg/g creatinine | 305.4 (63.2–953.7) | 96.0 (34.7–401.6) | 225.8 (63.8–793.0) | 774.9 (196.7–1928.8) | <0.001 |
| Hemoglobin, g/dL | 12.2±3.0 | 12.9±3.9 | 12.6±2.6 | 11.1±1.8 | <0.001 |
| Albumin, g/dL | 3.9±0.5 | 4.3±0.3 | 4.1±0.3 | 3.9±0.5 | <0.001 |
| Total cholesterol, mg/dL | 171.7±38.9 | 174.2±39.1 | 172.7±36.7 | 168.2±40.9 | 0.20 |
| LDL‐C, mg/dL | 84.1±39.5 | 82.7±39.2 | 85.1±37.7 | 84.6±41.6 | 0.78 |
| HDL‐C, mg/dL | 42.0±19.7 | 44.9±22.0 | 43.4±18.3 | 37.7±17.9 | <0.001 |
| Fasting glucose, mg/dL | 114.9±35.9 | 114.9±31.2 | 114.6±33.0 | 115.0±42.5 | 0.90 |
| HbA1c, % | 6.0±1.8 | 5.9±1.8 | 5.9±1.8 | 6.2±1.8 | 0.13 |
| CRP, mg/dL | 0.80 (0.50–1.60) | 0.70 (0.40–1.20) | 0.90 (0.50–1.70) | 0.90 (0.50–2.37) | 0.001 |
Data are presented as mean±SD, median (interquartile range), or number (percentage). CKD stages were defined on the basis of Kidney Disease: Improving Global Outcomes guidelines 2012. BMI indicates body mass index; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; CRP, C‐reactive protein; CVA, cerebrovascular accident; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; SBP, systolic blood pressure; suPAR, soluble urokinase‐type plasminogen activator receptor; and UACR, urine albumin/creatinine ratio.